Effects of continuity of care on health outcomes among patients with diabetes mellitus and/or hypertension: a systematic review

Kam-Suen Chan¹, Eric Yuk-Fai Wan¹,²*, Weng-Yee Chin¹, Will Ho-Gi Cheng¹, Margaret Kay Ho¹, Esther Yee-Tak Yu¹ and Cindy Lo-Kuen Lam¹

Abstract

Background: The rising prevalence of non-communicable diseases (NCDs) such as diabetes mellitus (DM) and hypertension (HT) has placed a tremendous burden on healthcare systems around the world, resulting in a call for more effective service delivery models. Better continuity of care (CoC) has been associated with improved health outcomes. This review examines the association between CoC and health outcomes in patients with DM and/or HT.

Methods: This was a systematic review with searches carried out on 13 March 2021 through PubMed, Embase, MEDLINE and CINAHL plus, clinical trials registry and bibliography reviews. Eligibility criteria were: published in English; from 2000 onwards; included adult DM and/or HT patients; examined CoC as their main intervention/exposure; and utilised quantifiable outcome measures (categorised into health indicators and service utilisation). The study quality was evaluated with Critical Appraisal Skills Programme (CASP) appraisal checklists.

Results: Initial searching yielded 21,090 results with 42 studies meeting the inclusion criteria. High CoC was associated with reduced hospitalisation (16 out of 18 studies), emergency room attendances (eight out of eight), mortality rate (six out of seven), disease-related complications (seven out of seven), and healthcare expenses (four out of four) but not with blood pressure (two out of 13), lipid profile (one out of six), body mass index (zero out of three). Six out of 12 studies on diabetic outcomes reported significant improvement in haemoglobin A1c by higher CoC. Variations in the classification of continuity of care and outcome definition were identified, making meta-analyses inappropriate. CASP evaluation rated most studies fair in quality, but found insufficient adjustment on confounders, selection bias and short follow-up period were common limitations of current literatures.

Conclusion: There is evidence of a strong association between higher continuity of care and reduced mortality rate, complication risks and health service utilisation among DM and/or HT patients but little to no improvement in various health indicators. Significant methodological heterogeneity in how CoC and patient outcomes are assessed limits the ability for meta-analysis of findings. Further studies comprising sufficient confounding adjustment and standardised definitions are needed to provide stronger evidence of the benefits of CoC on patients with DM and/or HT.
Keywords: Continuity of care, Diabetes mellitus, Hypertension, Mortality, Hospitalisation, Accident and emergency attendance

Background
The global prevalence of chronic non-communicable diseases (NCDs), such as diabetes mellitus (DM) and hypertension (HT), is rising rapidly. By 2030, deaths attributable to NCDs are predicted to be 52 million annually, compared to 36 million in 2008 [1]. Population aging and earlier development of NCDs have exacerbated the burden of disease on healthcare systems [2]. As opposed to communicable diseases, management for NCDs is typically long term and requires ongoing healthcare interventions, such as asymptomatic screening for early diagnosis and addressing adherence to long-term medications [3]. Based on the framework for integrated people-centred health services, the World Health Organization recommends the practice of continuity of care in primary healthcare to optimise the management on NCDs such as diabetes or hypertension [4].

Continuity of care, or the quality of care between patients and providers extending over time and beyond illness episodes, is a key pillar in a good primary care system [5]. Specifically, relational continuity refers to “a therapeutic relationship between a patient and one or more providers that spans various healthcare events and results in accumulated knowledge of the patient and care consistent with the patient’s needs” [6]. As providers gain more knowledge about the patient [7], they can tailor medical advice in subsequent consultations. A high level of continuity of care has also been associated with reduced mortality, fewer hospitalisations, lower healthcare expenses, improved medication compliance, and higher patient satisfaction [8–22].

Evaluating the effect of continuity of care on the health indicators of DM and/or HT patients is challenging due to high methodological heterogeneity amongst studies. Two previous reviews examining the effect of continuity of care on general populations highlighted the problems of inconsistent measurement of continuity of care [22, 23]. Both reviews stated that the number of high-quality studies focusing on continuity of care and health outcomes was insufficient. The effect of continuity of care on complication development or key disease monitoring indicators of DM and/or HT patients, including haemoglobin A1c (HbA1c) and blood pressure, remains difficult to interpret as there are conflicting results. To bridge the gap in evidence, this review aims to examine the association and effect of continuity on the management and outcomes for patients with DM and/or HT. Secondary objectives are to investigate the mechanisms behind the relationship, to assess the quality and strength of the existing evidence, and suggest possible considerations for the interpretation and application of these findings.

Methods

Literature search
A systematic literature search was conducted on 13 March 2021 using four databases (PubMed, Embase, MEDLINE and CINAHL plus), and one trial register (ClinicalTrial.gov). PubMed, Embase and MEDLINE were chosen as they were the most extensive and commonly used databases in medical field; CINAHL plus is specialised in publications for nursing and allied health professionals. Both Embase and MEDLINE were searched via Ovid while CINAHL plus was searched via EBSCOHost. Each database was searched separately. To reduce the risk of publication bias, a search was conducted in ClinicalTrial.gov. Citation searches were also performed on relevant articles obtained from the literature search. Four key inclusion criteria were: 1) patients with hypertension and/or diabetes mellitus; 2) continuity of care; 3) health outcomes, including health indicators and service utilisation; and 4) published in English and after year 2000. The full description of the electronic search terms can be found in Additional file 1.

Eligibility and screening
Inclusion and exclusion criteria were pre-specified and applied during the search. Studies were included if they were experimental or observational studies that satisfied the following criteria: 1) the subjects were adult patients (≥ 18 years old) with a diagnosis of diabetes mellitus and/or hypertension; 2) the effects of receiving a regular source of care were examined as the study intervention; 3) the study outcome of interests were standardised and measurable health outcomes, including DM/HT related complications, hospitalisation, accident & emergency (A&E) attendance, mortality rate, blood pressure, HbA1c, lipid profile, body mass index (BMI) and medical expenditure; and 4) were published in English from 2000 onwards. Exclusion criteria included review studies, qualitative studies, studies that focused on general population instead of on DM/HT patients only, or studies where the full texts were not available (e.g. conference abstracts only). Results from all searches were stored in Endnote X9. After removal of duplicate studies, three reviewers (K.S.C., W.H.G.C. and M.K.H.) independently screened the studies based on their titles and abstracts.
All search results were reviewed by at least two reviewers. Disputes regarding eligibility were discussed until a consensus was reached. Full texts of selected studies were retrieved and reviewed independently by all three authors. Studies were included upon agreement of all three reviewers, and in cases of disagreement, arbitration was carried out by a fourth reviewer (E.Y.F.W.).

Data extraction and quality assessment
Information including settings, study design, study population characteristics, sample size, subjects mean age, length of study, measurement of continuity of care, study outcomes, results, and discussion were extracted and compiled into a Microsoft Excel spreadsheet for analysis. For ease of comparison, outcomes of all included studies were sorted into two categories: i) health indicators and ii) service utilisation. Case Control Study Checklist and the Cohort Study Checklist of Critical Appraisal Skills Programme (CASP) appraisal checklists [24] were used to evaluate the quality and risks of bias of the included studies. This tool assists in the quality appraisal of the studies in three areas: validity, legitimacy, and local applicability of the findings concluded from studies [24]. Feasibility of meta-analysis was assessed based on three criteria i) comparable continuity of care assessment; ii) comparable outcomes; and iii) study quality and analysis feasibility.

Results
The initial search yielded 21,090 studies from the databases and 134 studies from the trial registry. After removing duplicates, screening of the remaining 19,130 studies identified 39 eligible studies. Citation searches of these 39 studies identified 66 potentially relevant articles. Of these, three studies met the eligibility criteria and were included in the review (Fig. 1, Table 1). Among the 42 studies included, seven focused on hypertension [7, 25–30], 32 on diabetes [13, 18, 30–60] and three examined both [10, 61, 62]. Most of them were retrospective cohort studies (31 studies), with a few being prospective cohort (five studies), cross-sectional (four studies), or case–control studies (two studies). These studies were conducted in United States (ten studies), Taiwan (nine studies), South Korea (nine studies), Canada (three studies), Australia (three studies), Malaysia (two studies), United Kingdom (one study), Portugal (one study), the Netherlands (one study), Finland (one study), Chile (one study) and Israel (one study). Most of the studies had a population age mean or median of between 50–70 years. The follow-up periods spanned from less than a year [32,
| Authors (year) | Country | Design | N    | Agea | Length (years) | CoC measurement | CoC cut-off | Results          |
|---------------|---------|--------|------|------|----------------|-----------------|-------------|------------------|
|                |         |        |      |      |                |                 |             | w/ Improvement   |
|                |         |        |      |      |                |                 |             | w/o improvement  |
| I. Health indicators |         |        |      |      |                |                 |             |                  |
| Hanninen, Takala et al. (2001) [31] | Finland | Cross-sectional | DM: 260 | <65 | 2 | Single ph. | Same ph. ≥ 2 years | HbA1c |
| Overland, Yue et al. (2001) [32] | Australia | Prospective cohort | DM: 479 | 50.7–67.0 | 0.5 | Single ph. | Single ph. | HbA1c |
| Parchman and Pugh (2002) [33] | United States | Prospective cohort | DM: 265 | 58.7 (9.7) | 2 | CoCI | No cut-off | HbA1c |
| Sherina, Teng et al. (2003) [49] | Malaysia | Cross-sectional | DM: 166 | 59.2 | <1 | UPCI | Median | HbA1c |
| Mainous, Koopman et al. (2004) [34] | United States | Prospective cohort | DM: 1400 | No summary | 6 | Usual ph./site by patient questionnaire | w/ usual ph./site | HbA1c |
| Litaker, Ritter et al. (2005) [50] | United States | Retrospective cohort | DM: 1448 | No summary | 1 | Single ph. | Same ph. for 1 year | Blood pressure |
| Fisher, Sloane et al. (2007) [25] | United States | Retrospective cohort | HT: 459 | 58.9 (148) | 2 | CoCI | 0.40 (low/med) 0.67 (med/high) | Blood pressure |
| Gulliford, Nathani et al. (2007) [35] | United Kingdom | Prospective cohort | DM: 193 | 65 | <1 | Experienced CoC by patient questionnaire | No cut-off | Blood pressure |
| Salzman, Yuen et al. (2006) [30] | United States | Retrospective cohort | HT: 287 | ≥18 | 3 | Single ph. | Same ph. of last 5 visits | Blood pressure |
| Dearinger, Wilson et al. (2008) [36] | United States | Retrospective cohort | DM: 101 | 61.8 | 3 | UPCI | 0.45 (low/high) | Blood pressure |
| Younge, Jani et al. (2012) [51] | United States | Retrospective cohort | DM: 484 | ≥18 | 2 | MMCI | Quartiles | HbA1c |
| Hanafi, Abdullah et al. (2015) [27] | Malaysia | Retrospective cohort | HT: 1060 | 62.0 (1.04) | 1 | UPCI | No cut-off | Blood pressure |
| Liao, Lin et al. (2015) [52] | Taiwan | Retrospective cohort | DM: 89,428 | 53.7 (11.1) | 10 | UPCI (ph. & site) | 1.0 in ph. (high) 1.0 in site (high) < 0.7 in both ph. & site (low) Others (med) | Complications (CVD, PVD, renal diseases and others) Hospitalisation Mortality rate |
| Lustman, Comaneshter et al. (2016) [42] | Israel | Retrospective cohort | DM: 23,294 | High UPCI: 61.1 Low UPCI: 59.7 | 2 | UPCI | 0.75 (low/high) | Mortality rate HbA1c Blood pressure |

HbA1c: Hemoglobin A1c; BMI: Body Mass Index; LDL: Low-Density Lipoprotein; CVD: Cardiovascular Disease; PVD: Peripheral Vascular Disease.
| Authors (year)          | Country          | Design               | N      | Age*     | Length (years) | CoC measurement | CoC cut-off        | Results                                                                 |
|------------------------|------------------|----------------------|--------|----------|----------------|----------------|------------------|-------------------------------------------------------------------------|
| Chang, Chien et al. (2018) [53] | Taiwan           | Retrospective cohort | DM: 26,063 | 55.8 (12.0) | 17             | CoCl            | 0.43 (low/med) 0.80 (med/high) | Complication (ESRD) Hospitalisation                                   |
| Jang, Choy et al. (2018) [54] | South Korea      | Retrospective cohort | DM: 3565 | No summary | 8              | CoCl            | 0.75 (low/hi)    | Complication (ESRD) Hospitalisation                                    |
| Khanam, Kitsos et al. (2019) [28] | Australia        | Retrospective cohort | HT: 37,425 | ≥ 18      | 3.5            | HHI            | 0.5 (low/med) 0.75 (med/high) 1 (max) | Blood pressure                                                        |
| Kim and Park (2019) [48] | South Korea      | Case–control         | DM: 55,558 | No death: 76.7 (7.0) w/ death: 76.7 (7.1) | 12             | UPCI (site)     | Lowest vs highest by SAS Rank | Mortality rate                                                        |
| Lee, Chun et al. (2019) [47] | South Korea      | Retrospective cohort | DM: 16,806 | > 45      | 12             | CoCl            | 0.75 (low/hi)    | Complication (thyroid disorder)                                      |
| Leniz and Gulliford (2019) [62] | Chile            | Cross-sectional     | HT: 1252 DM: 418 | ≥ 15 | 2              | Questionnaire   | No cut-off       | HbA1c Blood pressure                                                  |
| Nam, Lee et al. (2019) [55] | South Korea      | Case–control         | DM: 2373 | ≥ 20      | 10             | CoCl            | Median           | Complications (CVD, nephropathy and others) Healthcare expense         |
| Sousa Santos, Tavares Bello et al. (2019) [46] | Portugal         | Retrospective cohort | DM: 100 | Studied: 69.2 (106) Control: 67.2 (104) | 5              | Single ph.      | Same ph. ≥ 5 years | HbA1c Blood pressure BMI LDL                                          |
| Choi, Choi et al. (2020) [29] | South Korea      | Retrospective cohort | HT: 244,187 | ≥ 20      | 11             | CoCl            | 0.23, 0.36, 0.56 | Complication (CVD)                                                    |
| II. Service Utilisation                                                                                                                                  |
| Knight, Dowden et al. (2009) [56] | Canada           | Retrospective cohort | DM: 1143 | ≥ 65      | 3              | CoCl            | UPCI SECON       | Hospitalisation                                                        |
| Hong, Kang et al. (2010) [10]  | South Korea      | Retrospective cohort | HT: 858,927 DM: 268,220 | HT: 71.5 (5.0) DM: 70.6 (4.6) | 4              | CoCl            | 0.20 (low/med) 0.40 (med/high) | Hospitalisation A&E attendance                                        |
| Lin, Huang et al. (2010) [37] | Taiwan           | Retrospective cohort | DM: 6476 | 5.88 (1.27) | 5              | UPCI            | 0.47 (low/med) 0.75 (med/high) | Long-term hospitalisation                                              |
| Liu, Dou et al. (2010) [57]    | United States    | Retrospective cohort | DM: 3873 | 5.87 (5.83–5.91) | 2              | FCI (site)      | No cut-off        | A&E attendance                                                        |

*Age distribution.*
Table 1 (continued)

| Authors (year) | Country          | Design                | N         | Agea    | Length (years) | CoC measurement | CoC cut-off                  | Results                                                                 |
|----------------|------------------|-----------------------|-----------|---------|----------------|------------------|----------------------------|------------------------------------------------------------------------|
| Chen and Cheng (2011) [13] | Taiwan           | Retrospective cohort  | DM: 48,107 | 60.7 (11.3) | 7              | CoCl             | 0.47 (low/med) 0.86 (mid/high) | Hospitalisation A&E attendance Medication expense Healthcare expense |
| Robles and Anderson (2011) [7] | United States    | Retrospective cohort  | HT: 5590  | Low CoCl 76.2 | 1              | CoCl             | 0.106 (low/med) 0.236 (med/high) | Medication expense Hospitalisation A&E attendance |
| Worall and Knight (2011) [38] | Canada           | Retrospective cohort  | DM: 305   | 74.3(6.7) | 3              | UPCI             | 0.75 (low/high) | Mortality rate Hospitalisation A&E attendance |
| Chen, Tseng et al. (2013) [18] | Taiwan           | Retrospective cohort  | DM: 11,299 | 55.7(11.3) | 7              | CoCl             | 0.22 (low/med) 0.44 (med/high) | Hospitalisation A&E attendance |
| Hong and Kang (2013) [39] | South Korea      | Retrospective cohort  | DM: 68,469 | 53.6 (12.1) | 4              | CoCl             | 0.4, 0.6, 0.8, 1 | Mortality rate Hospitalisation Healthcare expense |
| Hussey, Schneider et al. (2014) [40] | United States   | Retrospective cohort  | DM: 166,654 | >65 | 2              | CoCl (ph/site) | No cut-off | Hospitalisation A&E attendance Complications (MI, renal diseases and others) Healthcare expense |
| Comino, Islam et al. (2015) [58] | Australia        | Retrospective cohort  | DM: 20,433 | ≥45 | 1.5 | UPCI | 0.80 | Hospitalisation |
| Cho, Nam et al. (2016) [59] | South Korea      | Retrospective cohort  | DM: 5163  | ≥20 | 9 | CoCl | 0.2, 0.4, 0.6, 0.8, 1 | Hospitalisation |
| Hsu, Chou et al. (2016) [41] | Taiwan           | Retrospective cohort  | DM: 3757  | No summary | 7 | CoCl | Low, medium, high (=1) | A&E attendance |
| Nam, Cho et al. (2016) [26] | South Korea      | Retrospective cohort  | HT: 3,460,700 | ≥20 | 3 | CoCl | 0.75 (low/high) | Hospitalisation |
| Pu and Chou (2016) [61] | Taiwan           | Retrospective cohort  | HT: 331,506 | DM: 82,181 | HT: w/ A&E: 71 No A&E: 66 DM: w/ A&E: 69 No A&E: 65 | 2 | HT: 0.46 (low/med) 0.82 (med/high) 0.72 (med/high) | A&E attendance |
| Authors (year)                          | Country           | Design            | N       | Age⁶ | Length (years) | CoC measurement | CoC cut-off | Results          | w/ Improvement | w/o improvement |
|--------------------------------------|-------------------|-------------------|---------|------|---------------|-----------------|-------------|------------------|----------------|----------------|
| Van Loenen, Faber et al. (2016) [43]  | the Netherlands   | Cross-sectional   | DM: 45,082 | No summary | 3              | ph. and patient questionnaires | No cut-off | Hospitalisation |
| Weir, McAlistier et al. (2016) [44]   | Canada            | Prospective cohort| DM: 285,231 | 53.0 (10.5) | 7              | UPCI            | 0.75 (low/high) | Mortality rate | Hospitalisation |
| Li (2019) [45]                        | Taiwan            | Retrospective cohort | DM: 4007 | High CoCI: 61.1 (10.6) Low CoCI: 60.8 (10.5) High UPCI: 61.1 (10.6) Low UPCI: 60.8 (10.5) | 3              | CoCI UPCI | Median (low/high) | Hospitalisation A&E attendance | Mortality rate |
| Chen and Cheng (2020) [60]            | Taiwan            | Retrospective cohort | DM: 57,965 | 56.3 | 4              | CoCI            | Tertiles | Hospitalisation |

HT Hypertension, DM Diabetes mellitus, ph. Physician, CoC Continuity of care, CoCI Continuity of care index, UPCI Usual provider continuity index, SECON Sequential continuity index, MMCI Modified modified continuity index, FCI Fragmentation of care index, HHI Herfindahl–Hirschman index, A&E Accident and emergency, HbA1c Haemoglobin A1c; “Blood pressure” refers to either systolic blood pressure, diastolic blood pressure and a combined target of the two, BMI Body mass index; “Lipid profile” (unless specified) refers to either levels of low density lipoprotein, high density lipoprotein, cholesterol or triglyceride, LDL Low-density lipoprotein; “Complications” refers to (but not limited to) onset of cardiovascular disease, end-stage renal disease etc., ESRD End-stage renal disease, CVD Cardiovascular diseases, MI Myocardial infarction, w/ With, w/o Without, N Number

⁶ Age summary was extracted based on the availability of the information by the following order: mean (SD), median (interquartile range), median, mean or range
to 17 years [53]; the most common length was 2 to 3 years (16 studies).

Meta-analysis was not performed due to the clear heterogeneity among studies, including differences in assessment methods and cut-off points of continuity of care, inclusion and exclusion criteria of participants and outcomes, as well as adjustment of confounders. There was also a lack of consistency in the reporting of effect size. Missing information such as the number of patients and cases in each group or the exact cut-off points of exposure in some studies made unification of effect size impossible.

**Continuity of care measurement tools**

Details of the definitions and formulae of all continuity of care measurement tools used in the reviewed studies are listed in Additional file 2. The two most frequently used continuity of care instruments were the continuity of care index (CoCI) (20 studies) [7, 10, 13, 18, 25, 26, 29, 33, 39–41, 45, 47, 53–56, 59–61] and usual provider continuity index (UPCI) (12 studies) [27, 36–38, 42, 44, 45, 48, 49, 52, 56, 58]. CoCI measures the dispersion of visits of a patient to different providers [63], which is calculated by \( \sum_{i=1}^{k} \frac{n_i^2 - N}{N(N-1)} \), where \( k \) is the number of providers, \( n_i \) is the number of visits to provider \( i \) and \( N \) is the total number of visits of the patient. UPCI measures the proportion of visits given by the most frequently visited provider, i.e. \( \frac{n_{max}}{N} \), where \( n_{max} \) is the number of attendances to the most frequently visited provider and \( N \) is the total number of visits of the patient. Five studies used ‘attendance to a single physician within a period of time’ to define continuity of care [30–32, 46, 50], two studies assessed continuity of care based on the location where medical services were provided, rather than on individual physicians [48, 57], and three examined both [34, 40, 52]. Explanations for why a certain method was used were rarely provided. Two studies used multiple continuity of care calculations and the findings were consistent among different measurements [45, 56]. Among studies that assessed the effect of continuity of care by categorization, there was no consistent definition for cut-off. The most common cut-off used was a UPCI or CoCI of 0.75 (7 studies) to indicate high level of continuity of care [26, 38, 42, 44, 47, 54, 56].

**Study outcomes categories**

The number of studies showing the effect of continuity of care on various outcome measures is summarised in Fig. 2.

**Health indicators**

Continuity of care was reported by six out of seven studies to reduce mortality [38, 39, 42, 44, 45, 48, 52]. The effect of continuity of care on HbA1c was frequently evaluated in studies focusing on DM patients, but findings were less consistent, with six of the twelve studies showing statistically significant improvements [33, 34, 36, 42, 46, 51]. Continuity of care had little effect on blood pressure, with only two [28, 42] out of 13 studies reported improvements [25, 27, 28, 30, 32, 34–36, 42, 46, 50, 51].

![Fig. 2](image-url)  
**Fig. 2** Summary of reported outcomes with/without significant improvement related to continuity of care. Note: For detailed breakdown of study outcomes, please refer to Additional file 4. “Complications” refers to (but not limited to) onset of cardiovascular disease, end-stage renal disease etc.; “BP” refers to either systolic blood pressure, diastolic blood pressure and a combined target of both; HbA1c = Haemoglobin A1c; “Lipid profile” refers to either levels of low-density lipoprotein, high density lipoprotein, cholesterol or triglyceride; BMI = Body mass index; A&E = Accident and emergency
None of the studies showed any improvement in lipid profile [32, 34, 36, 42, 46, 51] or BMI [31, 35, 46]. All seven studies that examined the risk of disease-related complications such as cardiovascular disease, end-stage renal disease found that continuity of care reduced complication risks [29, 40, 47, 52–55].

Service utilisation
Hospitalisation and Accident and Emergency (A&E) attendance were the two most frequently studied service utilisation outcomes. Out of 18 studies, 16 reported statistically significant reductions in hospitalisation rates for patients with higher continuity of care and all eight studies that investigated A&E attendance found improvements. Most of the studies measured disease-related service use only [10, 13, 18, 26, 37, 38, 40, 41, 43, 52, 53, 60, 61]. Five studies examined the correlation between continuity of care and all-cause service utilisation [41, 42, 44, 45, 56]. In both cases, increased levels of continuity of care were associated with significant reductions in service use. Four studies showed reduced overall healthcare expenses [13, 39, 40, 55] and one out of two studies reported reduced medication expenses [7, 13].

Quality of included studies
The quality of the studies was evaluated using the Critical Appraisal Skills Programme (CASP)’s Case Control Study Checklist for Kim et al. and the CASP Cohort Study Checklist for the rest (Additional file 3). One of the most common sources of bias was inadequate accounting for confounding factors, such as socioeconomic status [13, 26, 38, 39, 45, 47, 50] and disease severity and/or comorbidity [38, 40, 61]. Many studies used pre-existing databases for analyses and certain aspects of patient characteristics and/or health-seeking behaviour were not included due to lack of data. There were also potential issues with selection bias and local applicability of findings. Some studies excluded patients who died during the study period or within certain periods following baseline [7, 10, 39, 40, 58] which can bias against patients with greater disease severity. Narrow inclusion criteria reduce the generalisability of the studies. In Worrall and Knight and Hussey et al., only records of fee-for-service were used for analyses [38, 40]. In Litaker et al., patients were recruited from two veteran clinics in the same region [50]. Due to the calculation of proportions, it was quite common for studies using UPCI or CoCl to exclude patients with fewer than three to four attendances [10, 13, 18, 26, 36, 37, 39, 42, 44, 45, 61]. Whether such exclusions may affect the studies’ findings remains unclear. It was also difficult to evaluate whether the length of follow-up was sufficient, since there are no standardised recommendations for the study of continuity of care. Our review found that confounding factors, selection bias, and short follow-up periods were common study limitations.

Discussion
This review identified studies from a wide range of settings representing a broad range of healthcare systems. The potential influence of different contexts and a diverse range of outcomes were assessed and categorised accordingly to allow for robust comparisons to be made between studies. These categories reflect a logical progression of stages in the management and control of NCDs allowing for a comprehensive synthesis of the current evidence on the effect of continuity of care for patients with diabetes and/or hypertension.

Beneficial effects of continuity of care were reported more consistently for service utilisation, mortality and disease-related complications than for health indicators such as HbA1c, blood pressure. To better understand the potential mechanisms behind the beneficial effect on service utilisation, the principle of how continuity of care comes into play in healthcare provision must be considered. Continuity of care has been described as a three-layered concept that encompasses informational continuity, longitudinal continuity and interpersonal continuity [20]. Interpersonal continuity is the most frequently examined aspect of continuity of care. It refers to the sustained and ongoing caring relationship, which catalyses the delivery of patient-centred healthcare, between the physician and the patient [35, 64]. It also reflects mutual trust and responsibility in this relationship. Healthcare providers with high levels of continuity of care are able to communicate better with their patients and thus have a better knowledge of their patients’ disease history and current situation that might not be included in the patient’s medical records. A study found that higher continuity of care was associated with better quality of care among DM patients, including more HbA1c testing and eye or foot examinations [65]. Therefore, deterioration in patients’ conditions could be less likely to go undetected or untreated. Moreover, continuity of care improves patient satisfaction [35], facilitates higher patient self-care behaviours, compliance and adherence to physicians’ recommendations and regime, which could be the reason for reduced preventable hospital admissions [18, 33, 36].

The reasons behind a lack of significant results among studies in other outcome categories could be due to methodological limitations such as insufficient sample sizes, and use of short-term dynamic outcome measurements. Firstly, studies without significant findings often contained smaller sample sizes [25, 30–33, 36, 46, 51, 62]. Having a small or inadequately powered sample size can
affect the validity of results and may mask potential associations between continuity of care and study outcomes. Secondly, biochemical measurements might not be the most reflective or accurate indicators for the effectiveness of continuity of care due to their dynamic nature [34, 36]. Mainous III et al., found a positive association between better continuity of care and improved HbA1c, but not with blood pressure or low-lipoprotein cholesterol among DM patients suggesting the result could be because providers placed a higher priority on achieving glycaemic control for DM patients over other outcomes [34]. As a result, significant associations between glycaemic control and relational continuity of care might be more observable. A similar conclusion was reported by Dearinger et al. [36]. The authors noted that blood pressure is a "dynamic measurement that can be influenced by many factors at any given time", such as variation among operators which may have contributed to measurement bias [36]. Moreover, blood pressure measurement in the study was performed as part of the patient's normal consultation, rather than using more meticulous methods, such as ambulatory or home-based measurements, which may impact the level of accuracy in the measurement. This may partially explain why blood pressure was not seen as a significant outcome in association with continuity of care. Both studies highlight the importance of best practice measurements when it comes to evaluating patient health. Careful consideration is needed to discern whether such dynamic outcomes when measured in a study accurately translates to the patient's health and wellbeing.

Another issue identified in the reviewed studies was a lack of consistent cut-off points among studies that categorised levels of continuity of care into discrete groups. UPCI or CoCl at ≥0.75 was a relatively common definition for high continuity of care [26, 37, 38, 42, 44, 47, 54, 56]. However, a number of studies applied other definitions, for example, Robles et al.: CoCl ≥0.236 [7]; Dearinger et al.: UPCI ≥0.45 [36]; Hong et al.: CoCl ≥0.40 [10]; and Chen et al.: CoCl ≥0.44 [18]. As there is currently no consensus to what a high degree of continuity of care is, studies often defined their cut-offs based on the distribution of their study population, such as using the median and tertiles. While this might not have a great impact on the overall conclusion for individual studies, it reduces the comparability between studies and may have greater implications for policymaking to improve continuity in real-life settings, as there needs to be evidence-based aims for various health systems to strive towards.

In terms of the quality evaluation of included studies, consideration of confounding factors was one of the biggest challenges. Although most studies had controlled for confounding factors, it was unclear these adjustments were sufficiently comprehensive. Several factors were found to have a significant influence on continuity, such as patient’s perception on continuity, remoteness and characteristics of the patient, the physician or the healthcare organisation [66, 67], which could be potential confounders. Depending on the health system, socioeconomic status, which is known to have a significant correlation with health [68], may affect an individual's ability to continue seeing the same physician which would hence impact their continuity of care. Structure of the healthcare organisation can also have an impact, as continuity of care might be more difficult to sustain in larger group practices [69]. Therefore, it is important to adequately appraise the appropriate confounders to ensure a valid result.

The study context should also be considered in order to understand the nuances of the relationship between continuity of care and patient health outcomes. The studies included in this review took place across several countries, with different healthcare systems. The impact of culture on the physician–patient relationships and/or the actual patient outcomes may be an important confounding factor. For example, Taiwan's healthcare system offers free consultations with lenient referral practices. This might increase the likelihood of hospital admissions compared to if the study was performed in a country with stricter referral policies [37]. And in many European countries, continuity of care is a well-established concept, emphasized by both healthcare providers and patients [70–72]. These countries generally have strong primary care systems and have implemented various policies to promote continuity of care, such as mandating or providing financial incentives for patients to register with a primary care doctor [73, 74]. This might result in insignificant findings due to low levels of variability in continuity of care among patient populations [43]. While contextual factors do not necessary detract from the findings in these studies, they still need to be taken into consideration when applying the findings to policymaking in other settings.

There were several strengths to this review. Firstly, we studied a wide range of DM/HT-related outcomes. This enabled us to provide a more comprehensive narrative about the effect of relational continuity of care in DM and/or HT patients. Second, we summarised the common characteristics and limitations of existing literature to inform policy recommendations and future research. There were also several limitations. Firstly, no meta-analysis was performed. While we have provided an integrated summary on the associations of continuity of care with various DM/HT related outcomes, without meta-analysis, we are unable to examine the strength of such associations. However, given the heterogeneity,
incomplete information and pre-existing biases among the observational studies, results from a meta-analysis would be questionable if not spurious [75]. Second, we did not review the non-English literature which introduces English-language bias. As the implementation and effects of continuity of care may differ across healthcare settings (such as the influence of local health-seeking behaviours), excluding non-English studies can cause selection bias. Third, while we have used a systematic approach to minimize biases, our review protocol lacks prior registration.

One of the challenges encountered in this review was overcoming discrepancies in the definitions of high and low levels continuity. While our review took such classifications as stated in the selected studies, further research should explore how differences in these classifications may affect the resulting conclusions and their statistical significance. Also, as research in this field is still relatively incomplete, there is no consensus on the best way to measure continuity. While this study examined various measures such as CoC and UPCI, it may be worthwhile to further investigate into the strengths and weaknesses of each measure and how they might influence outcomes.

Conclusions
This review found strong associations between high continuity of care and reduced healthcare utilisation, mortality rate and complication risk in patients with diabetes and/or hypertension, but hardly any impact on various health indicators. Heterogeneity in patient selection, confounding adjustment and assessments of continuity of care and outcome variables remain major constraints in current literatures. A more standardised measurement of continuity of care is needed in order to provide more reliable and comparable evidence for its implementation as a healthcare policy.

Abbreviations
NCD: Non-communicable diseases; DM: Diabetes mellitus; HT: Hypertension; CoC: Continuity of care; HbA1c: Haemoglobin A1c; A&E: Accident & emergency; CASP: Critical Appraisal Skills Programme; CoCI: Continuity of care index; UPCI: Usual provider continuity index; BMI: Body mass index; LDL: Low-density lipoprotein cholesterol; CVD: Cardiovascular diseases; ESRD: End-stage renal disease; MI: Myocardial infarction; N: Number; SES: Socioeconomic status.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12875-021-01493-x.

Additional file 1. Full electronic search terms used in literature search.
Additional file 2. Definition and formula of continuity of care measurements.

Additional file 3. Result post-appraisal by Critical Appraisal Skills Programme (CASP) checklists.
Additional file 4. Number studies with significant improvement over the total number studies by each outcome.

Acknowledgements
Not applicable.

Authors’ contributions
K.S.C, E.Y.F.W, W.Y.C, and C.L.K.L contributed to the study design, review and edit the manuscript. K.S.C, W.H.G.C, M.K.H contributed to review process, draft, review and edit the manuscript. E.Y.T.Y contributed to review and edit the manuscript. The author(s) read and approved the final manuscript.

Funding
This study is supported by the Health and Medical Research Fund, Food and Health Bureau, the Government of HKSAR (Project no: CFS-HKU4). No funding organization has any role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation of the manuscript.

Availability of data and materials
No datasets were generated or analysed in this systematic review. All data extracted and used for the analysis was summarized in Table 1.

Declarations

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of the University of Hong Kong—the Hospital Authority Hong Kong West Cluster (reference number: UW 19–329). No individual or animal data was involved in this study, thus consent to participate is not applicable.

Consent for publication
Not applicable.

Competing interests
No known conflict of interests.

Author details
1 Department of Family Medicine and Primary Care, The University of Hong Kong, 3/F Ap Lei Chau Clinic, 161 Main Street, Ap Lei Chau, Hong Kong, China.
2 Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.

Received: 14 October 2020 Accepted: 17 June 2021
Published online: 03 July 2021

References
1. World Health Organization. A comprehensive global monitoring framework including indicators and a set of voluntary global targets for the prevention and control of noncommunicable diseases. Geneva: World Health Organization; 2012.
2. World Health Organization. The world health report 2002: reducing risks, promoting healthy life. World Health Organization; 2002.
3. WHO Package of Essential NCD Intervention (PEN). Service delivery and program management. New Delhi: WHO Collaborating Centre for Capacity Building and Research in Community-based Noncommunicable Disease Prevention and Control; 2018.
4. World Health Organization. Continuity and coordination of care: a practice brief to support implementation of the WHO Framework on integrated people-centred health services. 2018.
5. Gulliford M, Naithani S, Morgan M. What is ‘continuity of care’? J Health Serv Res Policy. 2006;11(4):248–50.
6. Haggerty J, Burge F, Lévesque J-F, Gass D, Pineault R, Beaulieu M-D, Santor D. Operational definitions of attributes of primary health care: consensus among Canadian experts. Ann Fam Med. 2007;5(4):336–44.

7. Robles S, Anderson GF. Continuity of care and its effect on prescription drug use among Medicare beneficiaries with hypertension. Med Care. 2011;49(5):516–21.

8. Romaine AM, Haber GS, Wensky GS, McCall GN. Primary care and specialty providers: an assessment of continuity of care, utilization, and expenditures. Med Care. 2014;52(12):1042–9.

9. Cheng S-H, Chen C-C, Hou Y-F. A longitudinal examination of continuity of care and avoidable hospitalization: evidence from a universal coverage health care system. Arch Intern Med. 2010;170(18):1671–7.

10. Hong JS, Kang HC, Kim J. Continuity of care for elderly patients with diabetes mellitus, hypertension, asthma, and chronic obstructive pulmonary disease in Korea. J Korean Med Sci. 2010;25(9):1259–71.

11. Cheng S-H, Hou Y-F, Chen C-C. Does continuity of care matter in a health care system that lacks referral arrangements? Health Policy Plan. 2011;26(2):157–62.

12. Cho KH, Lee SG, Jun B, Jung BY, Kim JH, Park EC. Effects of continuity of care on hospital admission in patients with type 2 diabetes: analysis of nationwide insurance data organization, structure and delivery of healthcare. BMC Health Serv Res. 2015;15(1):107.

13. Chen CC, Cheng SH. Better continuity of care reduces costs for diabetic patients. Ann Fam Med. 2011;9(4):293–4.

14. Hoertel N, Limosin F, Leleu H. Poor longitudinal continuity of care is associated with an increased mortality rate among patients with mental disorders: results from the French National Health Insurance Reimbursement Database. Eur Psychiatry. 2014;29(6):358–64.

15. Shin DW, Cheng SH. Continuity of care with doctors—a matter of life and death? A systematic review of continuity of care and mortality. BMJ Open. 2018;8(6):e021161.

16. Marchinko S, Clarke D. The wellness planner: empowerment, quality of life, and continuity of care in mental illness. Arch Psychiatr Nurs. 2011;25(4):284–93.

17. De Maeseneer JM, De Prins L, Gosset C, Heyerick J. Provider continuity in family medicine: does it make a difference for total health care costs? Ann Fam Med. 2003;1(3):144–8.

18. Hoertel N, Limosin F, Leleu H. Effect of continuity of care and multimorbidity, and continuity of care in patients with newly diagnosed type 2 diabetes: a longitudinal analysis. Med Care. 2013;51(3):231–7.

19. Hjortdahl P, Laerum E. Continuity of care in general practice: effect on patient satisfaction. BMJ. 1992;304:6837–1287.

20. Saultz JW. Defining and measuring interpersonal continuity of care. Ann Fam Med. 2003;1(5):134–43.

21. Beatte P, Dowdah M, Turner C, Michener L, Nelson R. Longitudinal continuity of care is associated with high patient satisfaction with physical therapy. Phys Ther. 2005;85(10):1046–52.

22. Pereira Gray DJ, Sidaway-Lee K, White E, Thorne A, Evans PH. Continuity of care and multimorbidity—a matter of life and death? A systematic review of continuity of care and mortality. BMJ Open. 2018;8(6):e020161.

23. Van Walraven C, Oake N, Jennings A, Forster AJ. The association between continuity of care and outcomes: a systematic and critical review. J Eval Clin Pract. 2010;16(5):947–56.

24. CAPS Cohort Study Checklist. https://capsc.uk.net/wp-content/uploads/2018/01/CAPS-Cohort-Study-Checklist_2018.pdf. Accessed 18 Apr 2021.

25. Fisher M, Sloane P, Edwards L, Gamble G. Continuity of care and hypertension control in a university-based practice. Ethn Dis. 2007;17(4):693–8.

26. Nam YS, Cho KH, Kang HC, Lee KS, Park EC. Greater continuity of care reduces hospital admissions in patients with hypertension: an analysis of nationwide health insurance data in Korea, 2011–2013. Health Policy. 2016;120(6):604–11.

27. Hanno AF, Abdulla A, Lee PY, Liew SM, Chia YC, Khoo EM. Personal continuity of care in a university-based primary care practice: impact on blood pressure control. PLoS One. 2015;10(7):e0134030.

28. Khanam MA, Kitoso A, Stankovich J, Castellino R, Jose M, Peterson GM, Wimmer B, Razi Zaidi T, Radford J. Association of continuity of care with diabetic outcomes: a systematic and critical review. J Eval Clin Pract. 2010;16(5):947–56.

29. Salzman BE, Yuen T, Hanley L, Brisson N, Barrett E, Altshuler M, Baker G, Miedel H, Chambers C. Blood pressure control and continuity of care in an urban, Academic Family Medicine Practice. Internet J Fam Pract. 2006;5(1). https://ispub.com/IJFP/5/1/9223. Accessed 09 Apr 2021.

30. Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Good continuity of care may improve quality of life in type 2 diabetes. Diabetes Res Clin Pract. 2001;51(1):21–7.

31. Overland J, Yue DK, Mira M. Continuity of care in diabetes: to whom does it matter? Diabetes Res Clin Pract. 2001;52(1):55–61.

32. Parnham ML, Pugh JA, Noel PH, Larre C. Continuity of care, self-management behaviors, and glucose control in patients with type 2 diabetes. Med Care. 2002;40(2):137–44.

33. Mainous AG 3rd, Koopman RJ, Gill JM, Baker R, Pearson WS. Relationship between continuity of care and diabetes control: evidence from the Third National Health and Nutrition Examination Survey. Ann J Public Health. 2004;94(1):66–70.

34. Guildford MC, Nathani S, Morgan M. Continuity of care and intermediate outcomes of type 2 diabetes mellitus. Fam Pract. 2007;24(3):245–51.

35. Deery S, Maden J, Sharif A, Leach C, Abdulrahman A. A longitudinal examination of continuity of care, multimorbidity, and adverse events in patients with diabetes. Med Care. 2015;53(8):560–7.

36. Litaker D, Ritter C, Ober S, Aron D. Continuity of care and cardiovascular disease in adult patients. J Fam Pract. 2003;52(1):21–7.

37. Lin W, Huang IC, Wang SY, Yang MC, Youn CL. Continuity of care associated with avoidable hospitalizations: evidence from Taiwan’s National Health Insurance scheme. Int J Qual Health Care. 2010;22(1):3–8.

38. Worrall G, Knight J. Continuity of care is good for elderly people with diabetes: retrospective cohort study of mortality and hospitalization. Can Fam Physician. 2011;57(1):e16–20.

39. Hong JS, Kang HC. Continuity of ambulatory care and health outcomes in adult patients with type 2 diabetes in Korea. Health Policy. 2013;109(2):158–65.

40. Hussey PS, Schneider EC, Rudin RS, Fox DS, Lai J, Pollack CE. Continuity and the costs of care for chronic disease. JAMA Intern Med. 2014;174(5):742–8.

41. Hou SH, Chou YJ, Pu C. The effect of continuity of care on emergency room use for diabetic patients varies by disease severity. J Epidemiol. 2016;26(8):413–9.

42. Lustman A, Cormaneshder H, Vinkes S. Interpersonal continuity of care and type two diabetes. Prim Care Diabetes. 2016;10(3):165–70.

43. Van Loenen T, Faber MJ, Westert GP, Van den Berg MJ. The impact of primary care organization on avoidable hospital admissions for diabetes in 23 countries. Scand J Prim Health Care. 2016;34(1):3–12.

44. Wein DL, McAlister FA, Majumdar SR, Ehrlich DT. The interplay between continuity of care, multimorbidity, and adverse events in patients with diabetes. Med Care. 2016;54(4):386–93.

45. Li YC. Continuity of care for newly diagnosed diabetic patients: a population-based study. PLoS One. 2019;14(8):e022137.

46. Sousa Santos F, Tavares Bello C, Roque C, Capitao R, Castro Fonseca R, Limbert C, Sequeira Duarte J, Oliveira M, Vasconcelos C. The effect of changing regular care provider in type 2 diabetes mellitus: a retrospective study. Acta Med Port. 2019;32(9):580–7.

47. Lee SA, Chun SY, Kim W, Ju YL, Choi OW, Park EC. Association between continuity of care and the onset of thyroid disorder among diabetes patients in Korea. Int J Environ Res Public Health. 2019;16(2):233.

48. Kim JH, Park EC. Can diabetes patients seeking a second hospital get better care? Results from nested case-control study. PLoS One. 2019;14(1):e0210809.

49. Sherina HH, Teng CL, Yasin S. Continuity of care of diabetic patients in a family practice clinic: how important is it? Asia Pac Fam Med. 2003;2(1):1–5.

50. Litaker D, Ritter C, Ober S, Anon D. Continuity of care and cardiovascular risk factor management: does care by a single clinician add to informational continuity provided by electronic medical records? Am J Manag Care. 2005;11(11):899–6.

51. Younge R, Jani B, Rosenthal D, Lin SX. Does continuity of care have an effect on diabetes quality measures in a teaching practice in an urban underserved community? J Health Care Poor Underserved. 2012;23(4):1558–65.

52. Liu-J, Lin Z-Y, Huang J-C, Hsu KH. The relationship between type 2 diabetic patients’ early medical care-seeking consistency to the same clinician and health care system and their clinical outcomes. Medicine. 2015;94(7):e554–e554.
53. Chang P-Y, Chien L-N, Bai C-H, Lin Y-F, Chiou H-Y. Continuity of care with physicians and risk of subsequent hospitalization and end-stage renal disease in newly diagnosed type 2 diabetes mellitus patients. Ther Clin Risk Manag. 2018;14:511–21.

54. Jiang YJ, Choy YS, Nam CM, Moon KT, Park E-C. The effect of continuity of care on the incidence of end-stage renal disease in patients with newly detected type 2 diabetic nephropathy: a retrospective cohort study. BMC Nephrol. 2018;19(1):1–2.

55. Nam JH, Lee C, Kim N, Park KY, Ha J, Yun J, Shin DW, Shin E. Impact of continuous care on health outcomes and cost for type 2 diabetes mellitus: analysis using national health insurance cohort database. Diabetes Metab J. 2019;43(6):776–84.

56. Knight JC, Dowden JJ, Worrall GJ, Gadag VG, Murphy MM. Does higher continuity of family physician care reduce hospitalizations in elderly people with diabetes? Popul Health Manag. 2009;12(2):81–6.

57. Liu CW, Einstadter D, Cebul RD. Care fragmentation and emergency department use among complex patients with diabetes. Am J Manag Care. 2010;16(8):413–20.

58. Comino EJ, Islam MDF, Tran DT, Jorm L, Flack J, Jalaludin B, Haas M, Harris MF. Association of processes of primary care and hospitalisation for people with diabetes: a record linkage study. Diabetes Res Clin Pract. 2013;108(2):296–305.

59. Cho KH, Nam CM, Young C, Jae-Woo C, Lee S-H, Eun-Chel P, Cho KH, Nam CM, Choi Y, Choi J-W, et al. Impact of continuity of care on preventable hospitalization of patients with type 2 diabetes: a nationwide Korean cohort study, 2002–10. Int J Qual Health Care. 2016;28(4):478–85.

60. Chen CC, Cheng SH. Care continuity and care coordination: a preliminary examination of their effects on hospitalization. Med Care Res Rev. 2020. https://doi.org/10.1177/1077558720903882.

61. Pu C, Chou YJ. The impact of continuity of care on emergency room use in a health care system without referral management: an instrumental variable approach. Ann Epidemiol. 2016;26(3):183–8.

62. Leniz J, Gullford MC. Continuity of care and delivery of diabetes and hypertensive care among regular users of primary care services in Chile: a cross-sectional study. BMJ Open. 2019;9(10):e027830.

63. Dreier J, Comanescu DS, Rosenbluth Y, Battar E, Bitterman H, Cohen AD. The association between continuity of care in the community and health outcomes: a population-based study. Israel J Health Policy Res. 2012;1(1):1–12.

64. Bloom B. Crossing the quality chasm: a new health system for the 21st century. JAMA. 2002;287(9):646–7.

65. Parchman ML, Burge SK. Continuity and quality of care in type 2 diabetes. J Fam Pract. 2002;51(7):619–24.

66. Alazri M, Heywood P, Neal RD, Leese B. Continuity of care: literature review and implications. Sultan Qaboos Univ Med J. 2007;7(3):197.

67. Christakis DA, Kazak AE, Wright JA, Zimmerman FI, Bassett AL, Connell FA. What factors are associated with achieving high continuity of care? Fam Med-Kansas City. 2004;36(1):55–60.

68. Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E. Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health. 2010;100(5):S186–96.

69. Baker R, Steafield J. What type of general practice do patients prefer? Exploration of practice characteristics influencing patient satisfaction. Br J Gen Pract. 1995;45(401):654–9.

70. Abouglihate A, Abel G, Elliott MN, Parker RA, Campbell J, Lyraziopoulos G, Roland M. Do English patients want continuity of care, and do they receive it? Br J Gen Pract. 2012;62(601):e567–75.

71. Bjorkelund C, Maan A, Murante AM, Hoffman K, De Maeseneer J, Farkas-Pall Z, Hjortdahl P, Nemerenco A, Boström KB, Lindblad U. Impact of continuity on quality of primary care: from the perspective of citizens’ preferences and multimorbidity-position paper of the European Forum for Primary Care. Qual Prim Care. 2013;21(3):193–204.

72. Stokes T, Tarrant C, Mainous AG, Schers H, Freeman G, Baker R. Continuity of care: is the personal doctor still important? A survey of general practitioners and family physicians in England and Wales, the United States, and The Netherlands. Ann Fam Med. 2005;3(4):353–9.

73. Kringos D, Boerma W, Bourgueil Y, Cartier T, Dedeu T, Hasvold T, Hutchison A, Lember M, Oleszczuk M, Pavlic DR. The strength of primary care in Europe: an international comparative study. Br J Gen Pract. 2013;63(616):e742–50.

74. Kringos D, Boerma W, Bourgueil Y, Cartier T, Dedeu T, Hasvold T, Hutchison A, Lember M, Oleszczuk M, Pavlic DR. The strength of primary care in Europe: an international comparative study. Br J Gen Pract. 2013;63(616):e742–50.

75. Egger M, Schneider M, Smith GD. Meta-analysis Spurious precision? Meta-analysis of observational studies. BMJ. 1998;316(7125):140–4.